Resistance to the macrocyclic lactone moxidectin is mediated in part by membrane transporter P-glycoproteins: Implications for control of drug resistant parasitic nematodes

International Journal for Parasitology: Drugs and Drug Resistance

Volumn 4, Issue 3, 2014, Pages 143-151

  Bygarski, Elizabeth E ^a   Prichard, Roger K ^b   Ardelli, Bernadette F ^a  

^a BRANDON UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

ABC systems; Caenorhabditis; Inhibition; Motility; Moxidectin; P glycoprotein; Pharyngeal pumping

Indexed keywords

CHLORIDE CHANNEL; GLUTAMATE GATED CHLORIDE CHANNEL; GLUTAMIC ACID DERIVATIVE; IVERMECTIN; MOXIDECTIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 10; MULTIDRUG RESISTANCE PROTEIN 12; MULTIDRUG RESISTANCE PROTEIN 13; MULTIDRUG RESISTANCE PROTEIN 14; MULTIDRUG RESISTANCE PROTEIN 15; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; MULTIDRUG RESISTANCE PROTEIN 6; MULTIDRUG RESISTANCE PROTEIN 7; MULTIDRUG RESISTANCE PROTEIN 8; MULTIDRUG RESISTANCE PROTEIN 9; PROTOZOAL PROTEIN; UNCLASSIFIED DRUG; AGAR; COLCHICINE; QUINIDINE; VERAPAMIL;

ANTIBIOTIC RESISTANCE; ARTICLE; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; CROSS RESISTANCE; GENE DELETION; GENE EXPRESSION; GENETIC TRANSCRIPTION; MULTIGENE FAMILY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; WILD TYPE; GENE DISRUPTION; GENE MUTATION; NEMATODE; PARASITE CONTROL; PHENOTYPE; POINT MUTATION; VELOCITY;

EID: 84904625084     PISSN: 22113207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpddr.2014.06.002     Document Type: Article

References (39)

1. Ardelli B.F., Prichard R.K. Effects of ivermectin and moxidectin on the transcription of genes coding for multidrug resistance associated proteins and behaviour in Caenorhabditis elegans. J. Nematol. 2008, 40:290-298.
2. Ardelli B.F., Prichard R.K. Inhibition of P-glycoprotein enhances sensitivity of Caenorhabditis elegans to ivermectin. Vet. Parasitol. 2013, 191:264-275.
3. Ardelli B.F., Stitt L.E., Tompkins J.B., Prichard R.K. A comparison of the effects of ivermectin and moxidectin on the nematode Caenorhabditis elegans. Vet. Parasitol. 2009, 165:96-108.
4. Ardelli B.F., Stitt L.E., Tompkins J.B. Inventory and analysis of ATP binding cassette (ABC systems) in Brugia malayi. Parasitology 2010, 137:1-18.
5. Bargmann C.I., Horvitz H.R. Chemosensory neurons with overlapping functions direct chemotaxis to multiple chemicals in C. elegans. Neuron 1991, 7(5):729-742.
6. Buechner M., Hall D.H., Bhatt H., Hedgecock E.M. Cystic canal mutants in Caenorhabditis elegans are defective in the apical membrane domain of the renal (excretory) cell. Dev. Biol. 1999, 214:227-241.
7. Campbell W.C. Ivermectin and Abamectin 1989, Springer-Verlag, New York.
8. Chin K.V., Chauhan S.S., Pastan I., Gottesman M.M. Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ. 1990, 1:361-365.
9. Cully D.F., Vassilatis D.K., Liu K.K., Paress P.S., Van der Ploeg L.H., Schaeffer J.M., Arena J.P. Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans. Nature 1994, 371:707-711.
10. Demain A.L., Sanchez S. Microbial drug discovery: 80 years of progress. J. Antibiot. 2009, 62:5-16.
11. Dent J.A., Davis M.W., Avery L. Avr-15 encodes a chloride channel subunit that mediates inhibitory glutamatergic neurotransmission and ivermectin sensitivity in Caenorhabditis elegans. EMBO J. 1997, 16:5867-5879.
12. Dent J.A., Mchardy M.S., Vassilatis D.M., Avery L. The genetics of ivermectin resistance in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:2674-2979.
13. Dicker A.J., Nisbet A.J., Skuce P.J. Gene expression changes in a P-glycoprotein (Tci-pgp-9) putatively associated with ivermectin resistance in Teladorsagia circumcincta. Int. J. Parasitol. 2011, 41:935-942.
14. Feng X.P., Hayashi J., Beech R.N., Prichard R.K. Study of the nematode putative GABA type-A receptor subunits for modulation by ivermectin. J. Neurochem. 2002, 83:870-878.
15. Gao A., Wang X., Xiang W., Liang H., Gao J., Yan Y. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by doramectin and nemadectin. J. Pharm. Pharmacol. 2010, 6:393-399.
16. Hibbs R.E., Gouaux E. Principles of activation and permeation in an anion-selective Cys-loop receptor. Nature 2011, 427:54-60.
17. Higgins C.F. ABC transporters: physiology, structure and mechanism - an overview. Res. Microbiol. 2001, 152:205-210.
18. James C.E., Davey M.W. Increased expression of ABC transport proteins is associated with ivermectin resistance in the model nematode Caenorhabditis elegans. Int. J. Parasitol. 2009, 39:213-220.
19. Janssen I.J.I., Krücken J., Demeler J., von Samson-Himmelstjerna G. Caenorhabditis elegans: modest increase of susceptibility to ivermectin in individual P-glycoprotein loss-of-function strains. Exp. Parasitol. 2013, 134:171-177.
20. Kiki-Mvouaka S., Menez C., Borin C., Lyazrhi F., Foucaud-Vignault M., Dupuy J., Collet X., Alvinerie M., Lespine A. Role of P-glycoprotein in the disposition of macrocyclic lactones: a comparison between ivermectin, eprinomectin, and moxidectin in mice. Drug Metab. Dispos. 2010, 38:573-580.
21. Laughton D.L., Lunt G.G., Wolstenholme A.J. Reporter gene constructs suggest that the Caenorhabditis elegans avermectin receptor beta-subunit is expressed solely in the pharynx. J. Exp. Biol. 1997, 200:1509-1514.
22. Lespine A., Ménez C., Bourguinat C., Prichard R. P-glycoproteins and other multidrug resistance transporters in the pharmacology of anthelmintics: prospects for reversing transport-dependent anthelmintic resistance. Int. J. Parasitol. Drugs Drug Resist. 2012, 2:58-75.
23. Ménez C., Sutra J.-F., Prichard R., Lespine A. Relative neurotoxicity of ivermectin and moxidectin in Mdr1ab (-/-) mice and effects on mammalian GABA(A) channel activity. PLoS Negl. Trop. Dis. 2012, 6:e1883.
24. Molento M.B., Prichard R.K. Effects of the multidrug-resistance-reversing agents verapamil and CL 347,099 on the efficacy of ivermectin or moxidectin against unselected and drug-selected strains of Haemonchus contortus in jirds (Meriones unguiculatus). Parasitol. Res. 1999, 85:1007-1011.
25. Molento M.B., Lifschitz A., Sallovitz J., Lanusse C., Prichard R. Influence of verapamil on the pharmacokinetics of the antiparasitic drugs ivermectin and moxidectin in sheep. Parasitol. Res. 2004, 92:121-127.
26. Omura S., Crump A. The life and times of ivermectin - a success story. Nat. Rev. Microbiol. 2004, 2:984-989.
27. Osei-Atweneboana M.Y., Eng J.K.L., Boakye D.A., Gyapong J.O., Prichard R.K. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two phase epidemiological study. Lancet 2007, 369:2021-2029.
28. Osei-Atweneboana M.Y., Awadzi K., Attah S.K., Boakye D.A., Gyapong J.O., Prichard R.K. Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus. PLoS Neg. Trop. Dis. 2011, 5(3):e998.
29. Paiement J.P., Leger C., Ribeiro P., Prichard R.K. Haemonchus contortus: effects of glutamate, ivermectin, and moxidectin on insulin uptake activity in unselected and ivermectin-selected adults. Exp. Parasitol. 1999, 92:193-198.
30. Pajic M., Iyer J.K., Kersbergen A., van der Burg E., Nygren A.O., Jonkers J., Borst P., Rottenberg S. Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. Cancer Res. 2009, 69:6396-6404.
31. Palmiera A., Sousa E., Vasconcelos M.H., Pinto M.M. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr. Med. Chem. 2012, 19:1946-2025.
32. Prichard R., Ménez C., Lespine A. Moxidectin and the avermectins: consanguinity but not identity. Int. J. Parasitol. Drugs Drug Resist. 2012, 2:134-153.
33. Schinkel A.H., Smit J.J.M., van Tellingen O., Beiinen J.H., Wagenarr E., van Deemter L., Mel C.A.A., van der Valk M.A., Robanus-Maandag E.C., te Riele H.P.J., Berns A.J.M., Borst P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77:491-502.
34. Shoop W.L., Mrozik H., Fisher M.H. Structure and activity of avermectins and milbemycins in animal health. Vet. Parasitol. 1995, 59:139-156.
35. Summers M.A., Moore J.L., McAuley J.W. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann. Pharmacother. 2004, 38:1631-1634.
36. Syvanen S., Hammarlund-Udenaes M. Using PET studies of P-gp function to elucidate mechanisms underlying the disposition of drugs. Curr. Top. Med. Chem. 2010, 10:1799-1809.
37. Williamson S.M., Storey B., Howell S., Harper K.M., Kaplan R.M., Wolstenholme A.J. Candidate anthelmintic resistance-associated gene expression and sequence polymorphism in a triple-resistant field isolate of Haemonchus contortus. Mol. Biochem. Parasitol. 2011, 180:99-105.
38. World Health Organization, 2009. New drug for river blindness begins Phase 3 clinical trial: moxidectin could dramatically speed up elimination of disease across Africa. WHO Press Release, 1 July 2009.
39. Zhao Z., Sheps J.A., Ling V., Fang L.L., Baillie D.L. Expression analysis of ABC transporters reveals differential functions of tandemly duplicated genes in Caenorhabditis elegans. J. Mol. Biol. 2004, 344:409-417.